Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Cancer drug development has moved from conventional cytotoxic chemotherapeutics to a more mechanism-based targeted approach towards the common goal of tumour growth arrest. The rapid progress in chromatin research and understanding epigenetic control has supplied a plethora of potential targets for intervention in cancer. Histone deacetylases (HDACs) have been widely implicated in growth and transcriptional control, and inhibition of HDAC activity using small molecules causes apoptosis in tumour cells. Here, we review HDAC inhibitors, together with their current status of clinical development and potential utility in cancer therapy.

Original publication

DOI

10.1179/joc.2004.16.Supplement-1.64

Type

Journal article

Journal

J Chemother

Publication Date

11/2004

Volume

16 Suppl 4

Pages

64 - 67

Keywords

Antineoplastic Agents, Apoptosis, Cell Proliferation, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Drug Delivery Systems, Drug Resistance, Neoplasm, Enzyme Inhibitors, Female, Histone Deacetylase Inhibitors, Histone Deacetylases, Humans, Male, Neoplasms, Risk Factors, Sensitivity and Specificity, Treatment Outcome